Quality of life and depressive symptoms
The effect of Zebinix(TM) on quality of life was analysed using the
Quality of Life Epilepsy Inventory-31 (QOLIE-31) scale. There was a
statistically and clinically significant improvement from baseline during
long-term open-label therapy, including:5
- 16 per cent mean relative improvement in overall quality of life
- 51 per cent improvement in worry about seizures (p<0.0001)
- 41 per cent improvement in social function (p<0.001)
Improvement in depressive symptoms was also measured using the Montgomery Asberg Depression Rating Scale (MADRS). Zebinix(TM) demonstrated a significant improvement in depressive mood and symptoms from baseline (p<0.0001).(6)
Notes to Editors
About partial seizures and their treatment
Epilepsy is one of the most common neurological diseases, affecting almost 1 in 100 people.(8) Treatment of partial seizures, the most common type of epilepsy, presents a constant challenge - up to 58% of patients with partial seizures do not achieve seizure control with current antiepileptic drugs.(9)
Furthermore, adverse events, such as dizziness and somnolence, are highly prevalent with existing anti-epileptic agents and may affect as many as 97% of patients.(10) Hence, there is a need for new anti-epileptic agents that offer effective reduction in seizure frequency combined with a favourable safety profile.
Epilepsy is characterised by abnormal firing of impulses from nerve cells in the brain. In partial-onset epilepsy, these bursts of electrical activity are initially focused in specific areas of the brain, but may become more generalised; the symptoms vary according to the affected areas. Nerve impulses are triggered via voltage-gated sodium channels in the nerve cell membrane.
Zebinix(TM) is a novel voltage-gated sodium chan
Copyright©2008 PR Newswire.
All rights reserved